Takeda Pharmaceutical Company Limited (TAK) is eagerly anticipating the FDA's decision on two of its drug candidates next month. First up, TAK-755, an enzyme replacement therapy, proposed for the treatment of congenital thrombotic thrombocytopenic purpura, is due for review on November 16. Congenital thrombotic thrombocytopenic purpura is an ultra-rare, chronic, and debilitating blood clotting disorder associated with life-threatening acute episodes and debilitating chronic symptoms. Following closely, Fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3, proposed for the treatment of adult patients with previously treated metastatic colorectal cancer, awaits the decision on November 30.TAK closed Friday’s trading at $13.47, up 0.67%.